title: An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases.
authors: Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892-1800, USA. marcg@intra.niddk.nih.gov
authors: Marc G
authors: MG
authors: Ghany
authors: David R
authors: DR
authors: Nelson
authors: Doris B
authors: DB
authors: Strader
authors: David L
authors: DL
authors: Thomas
authors: Leonard B
authors: LB
authors: Seeff
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D024882:Drug Resistance, Viral; D005260:Female; D005838:Genotype; D016174:Hepacivirus / Q000187:drug effects / Q000235:genetics*; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000235:genetics* / Q000503:physiopathology; D006801:Humans; D008297:Male; D009842:Oligopeptides / Q000627:therapeutic use; D011379:Prognosis; D011392:Proline / Q000031:analogs & derivatives / Q000627:therapeutic use; D011480:Protease Inhibitors / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic / Q000592:standards; D012008:Recurrence; D018570:Risk Assessment; D012955:Societies, Medical; D016896:Treatment Outcome; D014481:United States
chemical_list: D000998:Antiviral Agents; D009842:Oligopeptides; D011480:Protease Inhibitors; C486464:telaprevir; C512204:N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide; D011392:Proline